Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...

Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Expects more pronounced impact from newly launched products as the year progresses. STELARA biosimilar competition to ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

Ellsworth Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.0% during the fourth ...

City Holding Co. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.6% during the fourth ...